Published in J Clin Invest on February 01, 2002
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
DC-based cancer vaccines. J Clin Invest (2007) 3.81
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer (2004) 1.45
Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 1.38
Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26
Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med (2004) 1.22
Whole tumor antigen vaccines. Semin Immunol (2010) 1.19
Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood (2005) 1.16
High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors. Vaccine (2012) 1.12
CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol (2008) 1.05
Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol (2010) 1.05
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother (2011) 1.04
Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy (2010) 1.04
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01
Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol (2003) 1.01
Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics (2009) 1.00
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer (2005) 1.00
CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology (2007) 0.99
Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98
Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol (2007) 0.97
Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol (2014) 0.96
Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol (2004) 0.94
Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol (2012) 0.93
A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J Immunother (2012) 0.92
Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol (2008) 0.92
Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia (2006) 0.91
Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol (2011) 0.91
Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate (2010) 0.91
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Clin Cancer Res (2015) 0.90
Inclusion of high molecular weight dextran in calcium phosphate-mediated transfection significantly improves gene transfer efficiency. Cell Mol Biol (Noisy-le-grand) (2007) 0.89
Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther (2007) 0.88
RNA vaccines in cancer treatment. J Biomed Biotechnol (2010) 0.87
Spontaneous proliferation and type 2 cytokine secretion by CD4+T cells in patients with metastatic melanoma vaccinated with antigen-pulsed dendritic cells. J Clin Immunol (2005) 0.87
Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. Clin Exp Immunol (2005) 0.87
Tumor immunotherapy: inching toward the finish line. J Clin Invest (2002) 0.86
Enhancement of dendritic cells as vaccines for cancer. Immunotherapy (2010) 0.86
Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses. BMC Immunol (2011) 0.84
The immunotherapeutic potential of dendritic cells in type 1 diabetes. Clin Exp Immunol (2010) 0.84
Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol (2010) 0.84
Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genet Vaccines Ther (2005) 0.83
A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. J Transl Med (2005) 0.83
Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: a promising approach for the treatment of prostate cancer. Genet Vaccines Ther (2008) 0.82
Dendritic cell-based immunotherapy. Cell Res (2016) 0.81
Immunoregulatory effects of AFP domains on monocyte-derived dendritic cell function. BMC Immunol (2011) 0.81
Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity. Hum Vaccin Immunother (2015) 0.80
mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother (2013) 0.80
Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens. Cancer Immunol Immunother (2010) 0.80
Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell. Exp Biol Med (Maywood) (2015) 0.79
[Chemotherapy for prostate cancer]. Wien Klin Wochenschr (2008) 0.79
High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA. Clin Vaccine Immunol (2008) 0.78
RNA-Based Vaccines in Cancer Immunotherapy. J Immunol Res (2015) 0.78
Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response. Mol Ther Nucleic Acids (2013) 0.78
Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer. Vaccine (2015) 0.77
Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) (2013) 0.76
Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens. J Exp Clin Cancer Res (2016) 0.75
State of the art in tumor antigen and biomarker discovery. Cancers (Basel) (2011) 0.75
Monocyte-derived dendritic cells from patients with cervical intraepithelial lesions. Oncol Lett (2017) 0.75
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. J Immunol Res (2015) 0.75
Incomplete tumour control following DNA vaccination against rat gliomas expressing a model antigen. Acta Neurochir (Wien) (2012) 0.75
A generic RNA pulsed DC based approach for developing therapeutic intervention against Nasopharyngeal Carcinoma. Hum Vaccin Immunother (2016) 0.75
A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro. J Hematol Oncol (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med (2001) 4.78
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 4.15
The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) (1999) 3.94
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med (1996) 3.01
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med (1997) 1.82
Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate (1996) 1.73
Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol (1998) 1.64
HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol (2000) 1.55
Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst (2000) 1.53
Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods (1992) 1.44
Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol (2001) 1.36
Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol (2000) 1.32
Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother (1998) 1.19
Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate (2000) 1.09
Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol (2000) 1.03
Micrometastatic bone marrow involvement: detection and prognostic significance. Med Oncol (1999) 0.96
Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center. Semin Oncol (1999) 0.96
Prostate cancer, Incidence, management and outcomes. Drugs Aging (1998) 0.84
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (2010) 7.15
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol (2007) 4.32
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Low quality of evidence for robot-assisted laparoscopic prostatectomy: results of a systematic review of the published literature. Eur Urol (2010) 3.68
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol (2013) 3.58
GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol (2011) 3.30
GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol (2011) 3.02
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol (2009) 2.94
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol (2013) 2.76
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ (2012) 2.69
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA (2008) 2.67
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res (2003) 2.62
Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol (2006) 2.49
Prospective comparison of patient experience with colon imaging tests. Am J Med (2006) 2.42
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol (2007) 2.42
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
Screening for prostate cancer. Cochrane Database Syst Rev (2013) 2.29
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (2008) 2.26
Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res (2003) 2.24
Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells. J Leukoc Biol (2010) 2.22
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest (2008) 2.18
A critical assessment of the quality of reporting of randomized, controlled trials in the urology literature. J Urol (2007) 2.16
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 2.10
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol (2006) 1.94
GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol (2012) 1.90
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol (2004) 1.86
Pain after percutaneous nephrolithotomy: impact of nephrostomy tube size. J Endourol (2003) 1.83
Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol (2005) 1.82
Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood (2005) 1.80
Emerging clinical applications of RNA. Nature (2002) 1.76
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature (2010) 1.73
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther (2004) 1.71
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol (2004) 1.70
Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev (2004) 1.66
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol (2007) 1.65
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol (2008) 1.63
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol (2010) 1.63
Ureteral access sheath provides protection against elevated renal pressures during routine flexible ureteroscopic stone manipulation. J Endourol (2004) 1.63
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res (2006) 1.62
Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res (2007) 1.62
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol (2009) 1.61
Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol (2012) 1.60
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther (2004) 1.57
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma (2007) 1.55
Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 1.53
Family-level impact of the CHAMP Family Program: a community collaborative effort to support urban families and reduce youth HIV risk exposure. Fam Process (2004) 1.48
Evaluating the evidence: statistical methods in randomized controlled trials in the urological literature. J Urol (2008) 1.48
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol (2007) 1.46
Evidence-based urology in practice: publication bias. BJU Int (2010) 1.44
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol (2008) 1.42
Factors associated with the full publication of studies presented in abstract form at the annual meeting of the American Urological Association. J Urol (2007) 1.40
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother (2004) 1.40
Percutaneous cryoablation for recurrent low grade renal cell carcinoma after failed nephron-sparing surgery. Can J Urol (2013) 1.38
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol (2009) 1.38
How to perform a literature search. J Urol (2008) 1.37
Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant (2003) 1.37
Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol (2010) 1.34
Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res (2011) 1.34
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res (2005) 1.33
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol (2011) 1.31
The determinants of tumour immunogenicity. Nat Rev Cancer (2012) 1.28
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28
Trifecta nerve complex: potential anatomical basis for microsurgical denervation of the spermatic cord for chronic orchialgia. J Urol (2013) 1.28
Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res (2003) 1.27
Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer (2011) 1.27